There are currently 1498 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05014139
Recruiting
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Register for Updates
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
NCT05719441
Recruiting
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HI... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: 31443, Trinity Health and Wellness Center CRS, Dallas, Texas
Conditions: Acute HIV Infection
Register for Updates
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228
Recruiting
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medicati... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
03/24/2025
Locations: Dharma MD PA doing business as Southwest Family Medicine Associates, Dallas, Texas
Conditions: Asthma
Register for Updates
Evaluate REC-4881 in Patients with FAP
NCT05552755
Recruiting
This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP).
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/24/2025
Locations: Genetic Cancer Prevention Clinic - UT Southwestern, Dallas, Texas
Conditions: Familial Adenomatous Polyposis
Register for Updates
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/24/2025
Locations: Research Site, Dallas, Texas
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: HCA Medical City Dallas, Dallas, Texas +1 locations
Conditions: Ischemic Stroke, Systemic Embolism
Register for Updates
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
03/24/2025
Locations: Research Site, Dallas, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647
Recruiting
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: Research Site, Dallas, Texas
Conditions: Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Register for Updates
A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer
NCT06038578
Recruiting
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2025
Locations: Texas Oncology Dallas Methodist, Dallas, Texas +4 locations
Conditions: Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Register for Updates
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043
Recruiting
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: AnaptysBio Investigational Site 10-104, Dallas, Texas
Conditions: Ulcerative Colitis
Register for Updates
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
NCT05671835
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/21/2025
Locations: Baylor Scott & White Center for Advanced Heart & Lung Disease, Dallas, Texas
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
RECOVER-ENERGIZE Platform Protocol
NCT06404047
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Southwest Family Medicine Associates, Dallas, Texas
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates